363 related articles for article (PubMed ID: 15735050)
1. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands.
Hershberger PA; Vasquez AC; Kanterewicz B; Land S; Siegfried JM; Nichols M
Cancer Res; 2005 Feb; 65(4):1598-605. PubMed ID: 15735050
[TBL] [Abstract][Full Text] [Related]
2. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen.
Stabile LP; Davis AL; Gubish CT; Hopkins TM; Luketich JD; Christie N; Finkelstein S; Siegfried JM
Cancer Res; 2002 Apr; 62(7):2141-50. PubMed ID: 11929836
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
[TBL] [Abstract][Full Text] [Related]
4. Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant.
Evers NM; Wang S; van den Berg JH; Houtman R; Melchers D; de Haan LH; Ederveen AG; Groten JP; Rietjens IM
Chem Biol Interact; 2014 Sep; 220():222-30. PubMed ID: 25014417
[TBL] [Abstract][Full Text] [Related]
5. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
[TBL] [Abstract][Full Text] [Related]
6. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
Garon EB; Pietras RJ; Finn RS; Kamranpour N; Pitts S; Márquez-Garbán DC; Desai AJ; Dering J; Hosmer W; von Euw EM; Dubinett SM; Slamon DJ
J Thorac Oncol; 2013 Mar; 8(3):270-8. PubMed ID: 23399957
[TBL] [Abstract][Full Text] [Related]
9. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta.
Kumar A; Klinge CM; Goldstein RE
Int J Oncol; 2010 May; 36(5):1067-80. PubMed ID: 20372779
[TBL] [Abstract][Full Text] [Related]
10. Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells.
Dougherty SM; Mazhawidza W; Bohn AR; Robinson KA; Mattingly KA; Blankenship KA; Huff MO; McGregor WG; Klinge CM
Endocr Relat Cancer; 2006 Mar; 13(1):113-34. PubMed ID: 16601283
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells.
Hershberger PA; Stabile LP; Kanterewicz B; Rothstein ME; Gubish CT; Land S; Shuai Y; Siegfried JM; Nichols M
J Steroid Biochem Mol Biol; 2009 Aug; 116(1-2):102-9. PubMed ID: 19460433
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta.
Routledge EJ; White R; Parker MG; Sumpter JP
J Biol Chem; 2000 Nov; 275(46):35986-93. PubMed ID: 10964929
[TBL] [Abstract][Full Text] [Related]
13. Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor.
Schaufele F; Chang CY; Liu W; Baxter JD; Nordeen SK; Wan Y; Day RN; McDonnell DP
Mol Endocrinol; 2000 Dec; 14(12):2024-39. PubMed ID: 11117532
[TBL] [Abstract][Full Text] [Related]
14. Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.
Dutertre M; Smith CL
Mol Endocrinol; 2003 Jul; 17(7):1296-314. PubMed ID: 12714702
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma.
Niikawa H; Suzuki T; Miki Y; Suzuki S; Nagasaki S; Akahira J; Honma S; Evans DB; Hayashi S; Kondo T; Sasano H
Clin Cancer Res; 2008 Jul; 14(14):4417-26. PubMed ID: 18579664
[TBL] [Abstract][Full Text] [Related]
16. G protein-coupled estrogen receptor (GPER) mediates NSCLC progression induced by 17β-estradiol (E2) and selective agonist G1.
Liu C; Liao Y; Fan S; Tang H; Jiang Z; Zhou B; Xiong J; Zhou S; Zou M; Wang J
Med Oncol; 2015 Apr; 32(4):104. PubMed ID: 25744245
[TBL] [Abstract][Full Text] [Related]
17. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
[TBL] [Abstract][Full Text] [Related]
18. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor.
Gee AC; Carlson KE; Martini PG; Katzenellenbogen BS; Katzenellenbogen JA
Mol Endocrinol; 1999 Nov; 13(11):1912-23. PubMed ID: 10551784
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptors, antiestrogens, and non-small cell lung cancer.
Bogush TA; Dudko EA; Beme AA; Bogush EA; Kim AI; Polotsky BE; Tjuljandin SA; Davydov MI
Biochemistry (Mosc); 2010 Dec; 75(12):1421-7. PubMed ID: 21314611
[TBL] [Abstract][Full Text] [Related]
20. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Reiter R; Oh AS; Wellstein A; Riegel AT
Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
